Lunit vs Viz.ai
Two imaging AI companies operating on completely different clocks. Lunit works cancer detection across chest radiograph and mammography, where the failure is a missed lesion discovered months later and the evidence that matters comes from screening populations. Viz.ai works acute triage and notification, holding the first ever authorization in that category, where the failure is a delayed intervention measured in minutes and the product's real work is mobilising the treating team. Neither competes with the other, and a health system may well run both in different departments. What the pair shows is that imaging AI evidence is not interchangeable: a screening product must be judged on positive predictive value at your prevalence, and an acute product on time to treatment.
- Cancer imaging is the focus across chest radiograph and mammography, with a listed parent and regulatory footprints in multiple markets.
- The evidence base in screening populations is deeper than for most detection vendors, which is the setting where sensitivity and specificity both bite.
- For a screening programme, a vendor whose portfolio is built around cancer detection is a closer fit than an acute triage platform.
- Its stroke product holds the first ever authorization for computer aided triage and notification, and the platform mobilises the treating team rather than only flagging.
- The evidence measures care delivery rather than detection accuracy, which is the harder result and the one tied to patient benefit.
- For a time critical pathway the constraint is coordination rather than interpretation.
Side by Side
| Axis | L Lunit |
V Viz.ai |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
These operate on different clocks and the comparison is about which problem you have: cancer screening plays out over months and its failure is a missed lesion, while acute triage plays out over minutes and its failure is a delayed intervention. Viz.ai publishes no independent security attestation and no business associate terms.
Neither publishes subgroup performance, and in screening that gap is consequential because prevalence and presentation both vary by population, which changes positive predictive value more than sensitivity does.